Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

Completed · Not applicable · Has a placebo group

Conditions studied: Metabolic Syndrome

In brief

The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.

Key facts

Study ID

NCT02670382

Run by

Tufts University

People needed

24

Starts

2016-03-01

Expected to finish

2020-10-01

Last updated by the study team

2021-04-14

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• fasting plasma TG levels between 150 and 500 mg/dL
• C-reactive protein (CRP) levels ≥2 µg/mL
• at least one of the following criteria for the definition of metabolic syndrome:
• abdominal obesity (waist circumference >40 inches in men and >35 inches in women),
• hypertension (blood pressure ≥130/≥85 mmHg or use of anti-hypertensive medications), and
• fasting glucose ≥110 mg/dL.

You may not qualify if…

• high-fish diets (>2 fish meals/week)
• taking fish oil supplements or supplements containing EPA or DHA
• allergy to sardines
• allergy to sunflower oil
• regular use of anti-inflammatory medications (NSAID, COX inhibitors, corticosteroids)
• anticoagulant therapy
• alcohol consumption >7 drinks/week
• uncontrolled thyroid dysfunction
• insulin-dependent type 2 diabetes mellitus
• kidney or liver disease
• smoking
• alterations in coagulation
• use of lipid altering medications

Where it is running

• Jean Mayer Human Nutrition Research Center on Aging at Tufts University — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.